- Home
- ONCO vs PIRS Comparison
ONCO vs PIRS Comparison
Compare ONCO & PIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- PIRS
- Stock Information
- Founded
- ONCO 2018
- PIRS 2001
- Country
- ONCO United States
- PIRS United States
- Employees
- ONCO N/A
- PIRS N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- PIRS Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- PIRS Health Care
- Exchange
- ONCO Nasdaq
- PIRS Nasdaq
- Market Cap
- ONCO 24.1M
- PIRS 22.4M
- IPO Year
- ONCO 2022
- PIRS N/A
- Fundamental
- Price
- ONCO $1.27
- PIRS $15.87
- Analyst Decision
- ONCO
- PIRS
- Analyst Count
- ONCO 0
- PIRS 0
- Target Price
- ONCO N/A
- PIRS N/A
- AVG Volume (30 Days)
- ONCO 71.6K
- PIRS 35.2K
- Earning Date
- ONCO 11-26-2024
- PIRS 11-13-2024
- Dividend Yield
- ONCO N/A
- PIRS N/A
- EPS Growth
- ONCO N/A
- PIRS N/A
- EPS
- ONCO N/A
- PIRS N/A
- Revenue
- ONCO $1,463,746.00
- PIRS $1,352,000.00
- Revenue This Year
- ONCO N/A
- PIRS N/A
- Revenue Next Year
- ONCO N/A
- PIRS N/A
- P/E Ratio
- ONCO N/A
- PIRS N/A
- Revenue Growth
- ONCO N/A
- PIRS N/A
- 52 Week Low
- ONCO $1.27
- PIRS $6.20
- 52 Week High
- ONCO $21.40
- PIRS $22.32
- Technical
- Relative Strength Index (RSI)
- ONCO 20.68
- PIRS 38.32
- Support Level
- ONCO $1.70
- PIRS $15.69
- Resistance Level
- ONCO $2.53
- PIRS $16.97
- Average True Range (ATR)
- ONCO 0.28
- PIRS 0.63
- MACD
- ONCO -0.14
- PIRS -0.13
- Stochastic Oscillator
- ONCO 0.00
- PIRS 8.85
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.